Literature DB >> 6179964

Antigenic characterization of Cryptococcus neoformans serotypes and its application to serotyping of clinical isolates.

R Ikeda, T Shinoda, Y Fukazawa, L Kaufman.   

Abstract

Antigenic analysis of the four serotypes of Cryptococcus neoformans was carried out by slide agglutination with reciprocal adsorption methods. With this procedure the antigenic patterns of the serotypes were established. Serotypes A and D had antigenic factors 1, 2, 3, 7 and 1, 2, 3, 8, respectively. Serotypes B and C were found to have antigenic factors 1, 2, 4, 5 and 1, 4, 6, respectively. Factor sera, prepared according to the antigenic patterns demonstrated by adsorption studies, proved to be useful for rapidly and accurately identifying C. neoformans serotypes. Some patterns similar to those of the C. neoformans serotypes were observed in five other Cryptococcus species and two Candida species. The proton magnetic resonance spectra of polysaccharides from the C. neoformans serotypes correlated well with their antigenic characteristics. Phenol oxidase test reactions and growth at 37 degrees C were useful criteria for determining which yeasts should be chosen for clinical application of factor sera for serotyping of C. neoformans. Sixty-two Japanese isolates of C. neoformans were serotyped. Fifty-eight of these isolates were serotype A, three were serotype A-D, and one was serotype D.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6179964      PMCID: PMC272288          DOI: 10.1128/jcm.16.1.22-29.1982

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  22 in total

1.  Serologic grouping of Cryptococcus neoformans.

Authors:  D E Wilson; J E Bennett; J W Bailey
Journal:  Proc Soc Exp Biol Med       Date:  1968-03

2.  Evaluation of the Uni-Yeast-Tek kit for the identification of medically important yeasts.

Authors:  P I Bowman; D G Ahearn
Journal:  J Clin Microbiol       Date:  1975-10       Impact factor: 5.948

3.  A new genus, filobasidiella, the perfect state of Cryptococcus neoformans.

Authors:  K J Kwon-Chung
Journal:  Mycologia       Date:  1975 Nov-Dec       Impact factor: 2.696

4.  A new species of Filobasidiella, the sexual state of Cryptococcus neoformans B and C serotypes.

Authors:  K J Kwon-Chung
Journal:  Mycologia       Date:  1976 Jul-Aug       Impact factor: 2.696

5.  [Proton magnetic resonance spectrum and the immunological specificity of polysaccharides of Candida].

Authors:  T Shinoda
Journal:  Nihon Saikingaku Zasshi       Date:  1972-01

6.  Epidemiologic differences among serotypes of Cryptococcus neoformans.

Authors:  J E Bennett; K J Kwon-Chung; D H Howard
Journal:  Am J Epidemiol       Date:  1977-06       Impact factor: 4.897

7.  Six-hour pigmentation test for the identification of Cryptococcus neoformans.

Authors:  R L Hopfer; D Gröschel
Journal:  J Clin Microbiol       Date:  1976-08       Impact factor: 5.948

8.  Immune response to Cryptococcus neoformans soluble polysaccharide. I. Serological assay for antigen and antibody.

Authors:  T R Kozel; J Cazin
Journal:  Infect Immun       Date:  1972-01       Impact factor: 3.441

9.  Cryptococcus neoformans: size range of infectious particles from aerosolized soil.

Authors:  J B Neilson; R A Fromtling; G S Bulmer
Journal:  Infect Immun       Date:  1977-09       Impact factor: 3.441

10.  A colour reaction for the differentiation of ascomycetous and hemibasidiomycetous yeasts.

Authors:  J P Van Der Walt; V K Hopsu-Havu
Journal:  Antonie Van Leeuwenhoek       Date:  1976       Impact factor: 2.271

View more
  65 in total

1.  Capsular reactions of Cryptococcus neoformans with polyspecific and oligospecific polyclonal anticapsular antibodies.

Authors:  T C MacGill; R S MacGill; T R Kozel
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

2.  Difference in FKS1 gene sequences between serotypes A and D of Cryptococcus neoformans.

Authors:  Reiko Tanaka; Yumi Imanishi; Kazuko Nishimura
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

3.  Combination efficacy of voriconazole and amphotericin B in the experimental disease in immunodeficient mice caused by fluconazole-resistant Cryptococcus neoformans.

Authors:  Eriques Gonçalves Silva; Claudete Rodrigues Paula; Amanda Latercia Tranches Dias; Marilene Rodrigues Chang; Luciana da Silva Ruiz; Valderez Gambale; Renato Araujo Prates; Martha Simões Ribeiro
Journal:  Mycopathologia       Date:  2010-10-24       Impact factor: 2.574

4.  Production of agglutinating monoclonal antibody against antigen 8 specific for Cryptococcus neoformans serotype D.

Authors:  R Ikeda; S Nishimura; A Nishikawa; T Shinoda
Journal:  Clin Diagn Lab Immunol       Date:  1996-01

5.  Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice.

Authors:  Robert W Maitta; Kausik Datta; Andrew Lees; Shelley Sims Belouski; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

6.  Aggregation of Cryptococcus neoformans by surfactant protein D is inhibited by its capsular component glucuronoxylomannan.

Authors:  J K van de Wetering; F E J Coenjaerts; A B Vaandrager; L M G van Golde; J J Batenburg
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

7.  Specificity of Cryptococcus neoformans factor sera determined by enzyme-linked immunosorbent assay and dot enzyme assay.

Authors:  T Belay; R Cherniak; T Shinoda
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

8.  Capsular localization of the Cryptococcus neoformans polysaccharide component galactoxylomannan.

Authors:  Magdia De Jesus; André Moraes Nicola; Marcio L Rodrigues; Guilhem Janbon; Arturo Casadevall
Journal:  Eukaryot Cell       Date:  2008-10-24

9.  Cryptococcus neoformans var. grubii: separate varietal status for Cryptococcus neoformans serotype A isolates.

Authors:  S P Franzot; I F Salkin; A Casadevall
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

10.  Interference by hydroxyethyl starch used for vascular filling in latex agglutination test for cryptococcal antigen.

Authors:  L Millon; T Barale; M C Julliot; J Martinez; G Mantion
Journal:  J Clin Microbiol       Date:  1995-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.